JOP20200165A1 - عمليات ووسائط جديدة لتحضير محفزات إنزيم حلقي جوانيلات قابلة للذوبان - Google Patents

عمليات ووسائط جديدة لتحضير محفزات إنزيم حلقي جوانيلات قابلة للذوبان

Info

Publication number
JOP20200165A1
JOP20200165A1 JOP/2020/0165A JOP20200165A JOP20200165A1 JO P20200165 A1 JOP20200165 A1 JO P20200165A1 JO P20200165 A JOP20200165 A JO P20200165A JO P20200165 A1 JOP20200165 A1 JO P20200165A1
Authority
JO
Jordan
Prior art keywords
guanylate
catalysts
media
new processes
preparing soluble
Prior art date
Application number
JOP/2020/0165A
Other languages
Arabic (ar)
English (en)
Inventor
Ahmad Hashash
Song Xue
Takashi Nakai
Debra Jane Wallace
Yuguang Wang
William Kissel
Wayne C Schairer
Fenger Zhou
Vishnu Vardhan Reddy Karnati
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2018/076982 external-priority patent/WO2019161534A1/en
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of JOP20200165A1 publication Critical patent/JOP20200165A1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JOP/2020/0165A 2018-01-10 2019-01-10 عمليات ووسائط جديدة لتحضير محفزات إنزيم حلقي جوانيلات قابلة للذوبان JOP20200165A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862615678P 2018-01-10 2018-01-10
PCT/CN2018/076982 WO2019161534A1 (en) 2018-02-22 2018-02-22 Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators
PCT/US2019/013060 WO2019140095A1 (en) 2018-01-10 2019-01-10 Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators

Publications (1)

Publication Number Publication Date
JOP20200165A1 true JOP20200165A1 (ar) 2022-10-30

Family

ID=65279655

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0165A JOP20200165A1 (ar) 2018-01-10 2019-01-10 عمليات ووسائط جديدة لتحضير محفزات إنزيم حلقي جوانيلات قابلة للذوبان

Country Status (17)

Country Link
US (5) US11274096B2 (enExample)
EP (3) EP4570797A3 (enExample)
JP (2) JP7357621B2 (enExample)
KR (3) KR20250002720A (enExample)
CN (3) CN118184645A (enExample)
AU (3) AU2019206560B2 (enExample)
BR (1) BR112020013985A2 (enExample)
CA (1) CA3087943A1 (enExample)
CL (3) CL2020001814A1 (enExample)
ES (1) ES2963447T3 (enExample)
IL (3) IL314714A (enExample)
JO (1) JOP20200165A1 (enExample)
MA (2) MA71753A (enExample)
MX (3) MX2020007364A (enExample)
SG (1) SG11202006311SA (enExample)
TW (2) TWI888947B (enExample)
WO (1) WO2019140095A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563077B (zh) 2016-07-07 2026-03-10 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的新方法
US11274096B2 (en) 2018-01-10 2022-03-15 Cyclerion Therapeutics, Inc. Processes and intermediates for the preparation of soluble guanylate cyclase stimulators
CN118221651A (zh) * 2022-12-21 2024-06-21 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途
AU2023412228A1 (en) * 2022-12-21 2025-07-03 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2588465B1 (en) * 2010-06-30 2017-01-25 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EA033168B1 (ru) * 2013-03-15 2019-09-30 Сайклерион Терапьютикс, Инк. СТИМУЛЯТОРЫ sGC
EP3094327A1 (en) * 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
EP3194382B1 (en) 2014-09-17 2021-09-08 Cyclerion Therapeutics, Inc. Pyrazole derivatives as sgc stimulators
EA201790627A1 (ru) * 2014-09-17 2017-09-29 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ рГЦ
CA3006746C (en) 2015-11-30 2024-01-30 Ironwood Pharmaceuticals, Inc. Solid dispersions comprising a sgc stimulator
CN109563086B (zh) 2016-07-07 2023-05-23 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的方法
CN109563077B (zh) 2016-07-07 2026-03-10 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的新方法
US11274096B2 (en) 2018-01-10 2022-03-15 Cyclerion Therapeutics, Inc. Processes and intermediates for the preparation of soluble guanylate cyclase stimulators

Also Published As

Publication number Publication date
EP3737679C0 (en) 2023-09-06
US11274096B2 (en) 2022-03-15
SG11202006311SA (en) 2020-07-29
KR20200106920A (ko) 2020-09-15
AU2025202281A9 (en) 2025-05-15
AU2023270260B2 (en) 2026-01-29
AU2019206560B2 (en) 2023-08-24
US11708361B2 (en) 2023-07-25
MX2020007364A (es) 2020-11-18
US20220024909A1 (en) 2022-01-27
US12030874B2 (en) 2024-07-09
WO2019140095A8 (en) 2020-06-18
JP2021511299A (ja) 2021-05-06
IL319883A (en) 2025-05-01
CL2022000907A1 (es) 2022-10-21
ES2963447T3 (es) 2024-03-27
IL314714A (en) 2024-10-01
EP4570797A2 (en) 2025-06-18
IL275748B1 (en) 2024-09-01
KR20250002720A (ko) 2025-01-07
EP4570797A3 (en) 2025-09-03
IL275748A (en) 2020-08-31
KR20250048609A (ko) 2025-04-09
TW201932450A (zh) 2019-08-16
US20210053962A1 (en) 2021-02-25
IL275748B2 (en) 2025-01-01
JP2023182647A (ja) 2023-12-26
AU2025202281A1 (en) 2025-04-17
CA3087943A1 (en) 2019-07-18
MA51565A (fr) 2020-11-18
TW202402741A (zh) 2024-01-16
KR102739727B1 (ko) 2024-12-05
CN111902410B (zh) 2024-04-19
MA71753A (fr) 2025-05-30
US20240391911A1 (en) 2024-11-28
AU2023270260A1 (en) 2023-12-07
US20230339928A1 (en) 2023-10-26
TWI821237B (zh) 2023-11-11
CN111902410A (zh) 2020-11-06
EP4249469A2 (en) 2023-09-27
EP3737679B1 (en) 2023-09-06
MX2023000045A (es) 2023-02-01
JP7357621B2 (ja) 2023-10-06
JP7744955B2 (ja) 2025-09-26
CL2020001814A1 (es) 2020-11-06
EP4249469A3 (en) 2023-12-27
TWI888947B (zh) 2025-07-01
CN118221665A (zh) 2024-06-21
WO2019140095A1 (en) 2019-07-18
AU2019206560A1 (en) 2020-07-30
US12275724B2 (en) 2025-04-15
EP3737679A1 (en) 2020-11-18
US20250361228A1 (en) 2025-11-27
BR112020013985A2 (pt) 2020-12-01
CN118184645A (zh) 2024-06-14
CL2022000904A1 (es) 2022-10-21
MX2023000044A (es) 2023-02-01

Similar Documents

Publication Publication Date Title
IL282084A (en) Optimized truss foundations, adapters for optimized truss foundations, and related systems and methods
CL2019001554S1 (es) Automóvil.
EP3758293A4 (en) SERVICE UPGRADE MANAGEMENT PROCESS, DEVICE AND STORAGE MEDIA
MX2021006237A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
CL2018000947S1 (es) Automóvil
CL2020000174S1 (es) Automóvil.
CL2018002782A1 (es) Apósito modificado
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
MX2017015464A (es) Anticuerpos anti-tau y metodos de uso.
EP3689057A4 (en) PROCESS, DEVICE AND MEDIA READABLE INFORMATION BY RADIO PASSENGER
CR20190271A (es) Anticuerpos antitau y métodos de uso
MX2023000563A (es) Metodos y procesos para evaluacion no invasiva de variaciones geneticas.
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
CR20170100A (es) Indazoles sustituidos con bencilo como inhibidores bub1
MX2017001981A (es) Inhibidores de diana de rapamicina en celulas de mamifero de complejo 1 (mtorc1).
CL2018001940S1 (es) Automóvil
CL2016002667A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
EP3779516C0 (en) POSITIONING SYSTEM, BASE STATION AND POSITIONING METHOD
CL2020001201S1 (es) Automóvil.
JOP20200165A1 (ar) عمليات ووسائط جديدة لتحضير محفزات إنزيم حلقي جوانيلات قابلة للذوبان
BR112016026730A2 (pt) métodos de caracterização e tratamento de leucemia mieloide aguda
JOP20200244B1 (ar) مشتقات بلاديينوليد كعوامل تستهدف جسيمات الوصل لعلاج السرطان